{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:38:03Z","timestamp":1791959883231,"version":"4.3.4"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,3,20]],"date-time":"2018-03-20T00:00:00Z","timestamp":1521504000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007660","name":"Universiteit Antwerpen","doi-asserted-by":"publisher","award":["Research Fund"],"award-info":[{"award-number":["Research Fund"]}],"id":[{"id":"10.13039\/501100007660","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Flanders Impulse Program on Networks for Dementia Research","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"name":"EU\/EFPIA Innovative Medicines Initiative Joint Undertaking","award":["115372"],"award-info":[{"award-number":["115372"]}]},{"DOI":"10.13039\/501100003132","name":"Agentschap voor Innovatie door Wetenschap en Technologie","doi-asserted-by":"crossref","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/501100003132","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13195-018-0364-0","type":"journal-article","created":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T00:48:08Z","timestamp":1522802888000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Diagnostic value of cerebrospinal fluid tau, neurofilament, and progranulin in definite frontotemporal lobar degeneration"],"prefix":"10.1186","volume":"10","author":[{"given":"Joery","family":"Goossens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Bjerke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Van Mossevelde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobi","family":"Van den Bossche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Goeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"De Vil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Sieben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Cras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Paul","family":"De Deyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Van Broeckhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"van der Zee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0304-9785","authenticated-orcid":false,"given":"Sebastiaan","family":"Engelborghs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,20]]},"reference":[{"key":"364_CR1","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2165\/11533100-000000000-00000","volume":"24","author":"GD Rabinovici","year":"2010","unstructured":"Rabinovici GD, Miller BL. Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management. CNS Drugs. 2010;24:375\u201398. \n                    https:\/\/doi.org\/10.2165\/11533100-000000000-00000","journal-title":"CNS Drugs."},{"key":"364_CR2","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1126\/science.1134108","volume":"314","author":"M Neumann","year":"2006","unstructured":"Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130\u20133. \n                    https:\/\/doi.org\/10.1126\/science.1134108","journal-title":"Science."},{"key":"364_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1046\/j.0305-1846.2003.00481.x","volume":"30","author":"S Taniguchi","year":"2004","unstructured":"Taniguchi S, McDonagh AM, Pickering-Brown SM, Umeda Y, Iwatsubo T, Hasegawa M, et al. The neuropathology of frontotemporal lobar degeneration with respect to the cytological and biochemical characteristics of tau protein. Neuropathol Appl Neurobiol. 2004;30:1\u201318. \n                    https:\/\/doi.org\/10.1046\/j.0305-1846.2003.00481.x","journal-title":"Neuropathol Appl Neurobiol."},{"key":"364_CR4","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1093\/brain\/awh348","volume":"128","author":"A Graham","year":"2005","unstructured":"Graham A, Davies R, Xuereb J, Halliday G, Kril J, Creasey H, et al. Pathologically proven frontotemporal dementia presenting with severe amnesia. Brain. 2005;128:597\u2013605. \n                    https:\/\/doi.org\/10.1093\/brain\/awh348","journal-title":"Brain."},{"key":"364_CR5","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1093\/brain\/awm213","volume":"130","author":"S Alladi","year":"2007","unstructured":"Alladi S, Xuereb J, Bak T, Nestor P, Knibb J, Patterson K, et al. Focal cortical presentations of Alzheimer\u2019s disease. Brain. 2007;130:2636\u201345. \n                    https:\/\/doi.org\/10.1093\/brain\/awm213","journal-title":"Brain."},{"key":"364_CR6","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00401-014-1380-1","volume":"129","author":"DJ Irwin","year":"2015","unstructured":"Irwin DJ, Cairns NJ, Grossman M, McMillan CT, Lee EB, Van Deerlin VM, et al. Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine. Acta Neuropathol. 2015;129:469\u201391. \n                    https:\/\/doi.org\/10.1007\/s00401-014-1380-1","journal-title":"Acta Neuropathol."},{"key":"364_CR7","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1212\/WNL.51.6.1546","volume":"51","author":"D Neary","year":"1998","unstructured":"Neary D, Snowden J, Gustafson L. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51:1546\u201354.","journal-title":"Neurology."},{"key":"364_CR8","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1093\/brain\/awr179","volume":"134","author":"K Rascovsky","year":"2011","unstructured":"Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456\u201377. \n                    https:\/\/doi.org\/10.1093\/brain\/awr179","journal-title":"Brain."},{"key":"364_CR9","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1212\/WNL.0b013e31821103e6","volume":"76","author":"ML Gorno-Tempini","year":"2011","unstructured":"Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76:1006\u201314. \n                    https:\/\/doi.org\/10.1212\/WNL.0b013e31821103e6","journal-title":"Neurology."},{"key":"364_CR10","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","volume":"13","author":"B Dubois","year":"2014","unstructured":"Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer\u2019s disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614\u201329. \n                    https:\/\/doi.org\/10.1016\/S1474-4422\n                    \n                  (14)70090-0","journal-title":"Lancet Neurol."},{"key":"364_CR11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3389\/fnagi.2013.00006","volume":"5","author":"DJ Irwin","year":"2013","unstructured":"Irwin DJ, Trojanowski JQ, Grossman M. Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer\u2019s disease. Front Aging Neurosci. 2013;5:6. \n                    https:\/\/doi.org\/10.3389\/fnagi.2013.00006","journal-title":"Front Aging Neurosci."},{"key":"364_CR12","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/ana.21621","volume":"65","author":"K Sleegers","year":"2009","unstructured":"Sleegers K, Brouwers N, Van Damme P, Engelborghs S, Gijselinck I, van der Zee J, et al. Serum biomarker for progranulin-associated frontotemporal lobar degeneration. Ann Neurol. 2009;65:603\u20139. \n                    https:\/\/doi.org\/10.1002\/ana.21621","journal-title":"Ann Neurol."},{"key":"364_CR13","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1212\/01.wnl.0000325058.10218.fc","volume":"71","author":"R Ghidoni","year":"2008","unstructured":"Ghidoni R, Benussi L, Glionna M, Franzoni M, Binetti G. Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration. Neurology. 2008;71:1235\u20139. \n                    https:\/\/doi.org\/10.1212\/01.wnl.0000325058.10218.fc","journal-title":"Neurology."},{"key":"364_CR14","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1159\/000448896","volume":"17","author":"C Wilke","year":"2016","unstructured":"Wilke C, Gillardon F, Deuschle C, Hobert MA, Jansen IE, Metzger FG, et al. Cerebrospinal fluid progranulin, but not serum progranulin, is reduced in GRN-negative frontotemporal dementia. Neurodegener Dis. 2016;17:83\u20138. \n                    https:\/\/doi.org\/10.1159\/000448896","journal-title":"Neurodegener Dis."},{"key":"364_CR15","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s00702-015-1486-1","volume":"123","author":"E Feneberg","year":"2016","unstructured":"Feneberg E, Steinacker P, Volk AE, Weishaupt JH, Wollmer MA, Boxer A, et al. Progranulin as a candidate biomarker for therapeutic trial in patients with ALS and FTLD. J Neural Transm. 2016;123:289\u201396. \n                    https:\/\/doi.org\/10.1007\/s00702-015-1486-1","journal-title":"J Neural Transm."},{"key":"364_CR16","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1212\/WNL.0000000000000445","volume":"82","author":"AM Nicholson","year":"2014","unstructured":"Nicholson AM, Finch NA, Thomas CS, Wojtas A, Rutherford NJ, Mielke MM, et al. Progranulin protein levels are differently regulated in plasma and CSF. Neurology. 2014;82:1871\u20138. \n                    https:\/\/doi.org\/10.1212\/WNL.0000000000000445","journal-title":"Neurology."},{"key":"364_CR17","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3233\/JAD-150746","volume":"50","author":"E Morenas-Rodr\u00edguez","year":"2015","unstructured":"Morenas-Rodr\u00edguez E, Cervera-Carles L, Vilaplana E, Alcolea D, Carmona-Iragui M, Dols-Icardo O, et al. Progranulin protein levels in cerebrospinal fluid in primary neurodegenerative dementias. J Alzheimers Dis. 2015;50:539\u201346. \n                    https:\/\/doi.org\/10.3233\/JAD-150746","journal-title":"J Alzheimers Dis."},{"key":"364_CR18","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S1474-4422(03)00530-1","volume":"2","author":"K Blennow","year":"2003","unstructured":"Blennow K, Hampel H. CSF markers for incipient Alzheimer\u2019s disease. Lancet Neurol. 2003;2:605\u201313. \n                    https:\/\/doi.org\/10.1016\/S1474-4422\n                    \n                  (03)00530-1","journal-title":"Lancet Neurol."},{"key":"364_CR19","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1515\/CCLM.2011.086","volume":"49","author":"AC van Harten","year":"2011","unstructured":"van Harten AC, Kester MI, Visser P-J, Blankenstein MA, Pijnenburg YA, van der Flier WM, et al. Tau and p-tau as CSF biomarkers in dementia: a meta-analysis. Clin Chem Lab Med. 2011;49:353\u201366. \n                    https:\/\/doi.org\/10.1515\/CCLM.2011.086","journal-title":"Clin Chem Lab Med."},{"key":"364_CR20","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3233\/JAD-160366","volume":"55","author":"A Rivero-Santana","year":"2017","unstructured":"Rivero-Santana A, Ferreira D, Perestelo-P\u00e9rez L, Westman E, Wahlund L-O, Sarr\u00eda A, et al. Cerebrospinal fluid biomarkers for the differential diagnosis between Alzheimer\u2019s disease and frontotemporal lobar degeneration: systematic review, HSROC analysis, and confounding factors. J Alzheimers Dis. 2017;55:625\u201344. \n                    https:\/\/doi.org\/10.3233\/JAD-160366","journal-title":"J Alzheimers Dis."},{"key":"364_CR21","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1212\/01.wnl.0000436625.63650.27","volume":"81","author":"WT Hu","year":"2013","unstructured":"Hu WT, Watts K, Grossman M, Glass J, Lah JJ, Hales C, et al. Reduced CSF p-tau181 to tau ratio is a biomarker for FTLD-TDP. Neurology. 2013;81:1945\u201352. \n                    https:\/\/doi.org\/10.1212\/01.wnl.0000436625.63650.27","journal-title":"Neurology."},{"key":"364_CR22","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3109\/21678421.2014.971812","volume":"16","author":"B Borroni","year":"2015","unstructured":"Borroni B, Benussi A, Archetti S, Galimberti D, Parnetti L, Nacmias B, et al. CSF p-tau181\/tau ratio as biomarker for TDP pathology in frontotemporal dementia. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:86\u201391. \n                    https:\/\/doi.org\/10.3109\/21678421.2014.971812","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener."},{"key":"364_CR23","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jns.2005.03.015","volume":"233","author":"A Petzold","year":"2005","unstructured":"Petzold A. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci. 2005;233:183\u201398. \n                    https:\/\/doi.org\/10.1016\/j.jns.2005.03.015","journal-title":"J Neurol Sci."},{"key":"364_CR24","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.mcn.2007.03.007","volume":"35","author":"MJ Strong","year":"2007","unstructured":"Strong MJ, Volkening K, Hammond R, Yang W, Strong W, Leystra-Lantz C, et al. TDP43 is a human low molecular weight neurofilament (hNFL) mRNA-binding protein. Mol Cell Neurosci. 2007;35:320\u20137. \n                    https:\/\/doi.org\/10.1016\/j.mcn.2007.03.007","journal-title":"Mol Cell Neurosci."},{"key":"364_CR25","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1136\/jnnp.2006.107326","volume":"78","author":"D de Jong","year":"2007","unstructured":"de Jong D, Jansen RWMM, Pijnenburg YAL, van Geel WJA, Borm GF, Kremer HPH, et al. CSF neurofilament proteins in the differential diagnosis of dementia. J Neurol Neurosurg Psychiatry. 2007;78:936\u20138. \n                    https:\/\/doi.org\/10.1136\/jnnp.2006.107326","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"364_CR26","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1471-2377-13-54","volume":"13","author":"M Landqvist Wald\u00f6","year":"2013","unstructured":"Landqvist Wald\u00f6 M, Frizell Santillo A, Passant U, Zetterberg H, Rosengren L, Nilsson C, et al. Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia. BMC Neurol. 2013;13:54. \n                    https:\/\/doi.org\/10.1186\/1471-2377-13-54","journal-title":"BMC Neurol."},{"key":"364_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-009-0612-2","volume":"119","author":"IRA Mackenzie","year":"2010","unstructured":"Mackenzie IRA, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol. 2010;119:1\u20134. \n                    https:\/\/doi.org\/10.1007\/s00401-009-0612-2","journal-title":"Acta Neuropathol."},{"key":"364_CR28","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00401-011-0845-8","volume":"122","author":"IRA Mackenzie","year":"2011","unstructured":"Mackenzie IRA, Neumann M, Baborie A, Sampathu DM, Du Plessis D, Jaros E, et al. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol. 2011;122:111\u20133. \n                    https:\/\/doi.org\/10.1007\/s00401-011-0845-8","journal-title":"Acta Neuropathol."},{"key":"364_CR29","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.3233\/JAD-140405","volume":"42","author":"S Van der Mussele","year":"2014","unstructured":"Van der Mussele S, Fransen E, Struyfs H, Luyckx J, Mari\u00ebn P, Saerens J, et al. Depression in mild cognitive impairment is associated with progression to Alzheimer\u2019s disease: a longitudinal study. J Alzheimers Dis. 2014;42:1239\u201350. \n                    https:\/\/doi.org\/10.3233\/JAD-140405","journal-title":"J Alzheimers Dis."},{"key":"364_CR30","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.neurobiolaging.2007.02.016","volume":"29","author":"S Engelborghs","year":"2008","unstructured":"Engelborghs S, De Vreese K, Van de Casteele T, Vanderstichele H, Van Everbroeck B, Cras P, et al. Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol Aging. 2008;29:1143\u201359. \n                    https:\/\/doi.org\/10.1016\/j.neurobiolaging.2007.02.016","journal-title":"Neurobiol Aging."},{"key":"364_CR31","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2217\/bmm.12.46","volume":"6","author":"M Del Campo","year":"2012","unstructured":"Del Campo M, Mollenhauer B, Bertolotto A, Engelborghs S, Hampel H, Simonsen AH, et al. Recommendations to standardize preanalytical confounding factors in Alzheimer\u2019s and Parkinson\u2019s disease cerebrospinal fluid biomarkers: an update. Biomark Med. 2012;6:419\u201330. \n                    https:\/\/doi.org\/10.2217\/bmm.12.46","journal-title":"Biomark Med."},{"key":"364_CR32","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1471-2105-12-77","volume":"12","author":"X Robin","year":"2011","unstructured":"Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J-C, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011;12:77. \n                    https:\/\/doi.org\/10.1186\/1471-2105-12-77","journal-title":"BMC Bioinformatics."},{"key":"364_CR33","doi-asserted-by":"publisher","first-page":"352","DOI":"10.2981\/08-057","volume":"15","author":"JA Gude","year":"2009","unstructured":"Gude JA, Mitchell MS, Ausband DE, Sime CA, Bangs EE. Internal validation of predictive logistic regression models for decision-making in wildlife management. Wildl Biol. 2009;15:352\u201369. \n                    https:\/\/doi.org\/10.2981\/08-057","journal-title":"Wildl Biol."},{"key":"364_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-011-0910-3","volume":"123","author":"TJ Montine","year":"2012","unstructured":"Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, et al. National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease: a practical approach. Acta Neuropathol. 2012;123:1\u201311. \n                    https:\/\/doi.org\/10.1007\/s00401-011-0910-3","journal-title":"Acta Neuropathol."},{"key":"364_CR35","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1212\/WNL.58.12.1791","volume":"58","author":"DR Thal","year":"2002","unstructured":"Thal DR, R\u00fcb U, Orantes M, Braak H. Phases of Abeta deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791\u2013800. \n                    https:\/\/doi.org\/10.1212\/WNL.58.12.1791","journal-title":"Neurology."},{"key":"364_CR36","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1212\/WNL.41.4.479","volume":"41","author":"SS Mirra","year":"1991","unstructured":"Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The Consortium to Establish a Registry for Alzheimer\u2019s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer\u2019s disease. Neurology. 1991;41:479\u201386.","journal-title":"Neurology."},{"key":"364_CR37","doi-asserted-by":"publisher","first-page":"654","DOI":"10.2174\/1567205013666160314151247","volume":"13","author":"C Wilke","year":"2016","unstructured":"Wilke C, Gillardon F, Deuschle C, Dubois E, Hobert MA. M\u00fcller vom Hagen J, et al. Serum levels of progranulin do not reflect cerebrospinal fluid levels in neurodegenerative disease. Curr Alzheimer Res. 2016;13:654\u201362. \n                    https:\/\/doi.org\/10.2174\/1567205013666160314151247","journal-title":"Curr Alzheimer Res."},{"key":"364_CR38","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1159\/000447738","volume":"6","author":"LHH Meeter","year":"2016","unstructured":"Meeter LHH, Patzke H, Loewen G, Dopper EGP, Pijnenburg YAL, van Minkelen R, et al. Progranulin levels in plasma and cerebrospinal fluid in granulin mutation carriers. Dement Geriatr Cogn Dis Extra. 2016;6:330\u201340. \n                    https:\/\/doi.org\/10.1159\/000447738","journal-title":"Dement Geriatr Cogn Dis Extra."},{"key":"364_CR39","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/acn3.274","volume":"3","author":"S Janelidze","year":"2016","unstructured":"Janelidze S, Zetterberg H, Mattsson N, Palmqvist S, Vanderstichele H, Lindberg O, et al. CSF A\u03b242\/A\u03b240 and A\u03b242\/A\u03b238 ratios: better diagnostic markers of Alzheimer disease. Ann Clin Transl Neurol. 2016;3:154\u201365. \n                    https:\/\/doi.org\/10.1002\/acn3.274","journal-title":"Ann Clin Transl Neurol."},{"key":"364_CR40","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.dadm.2015.11.001","volume":"1","author":"YAL Pijnenburg","year":"2015","unstructured":"Pijnenburg YAL, Verwey NA, van der Flier WM, Scheltens P, Teunissen CE. Discriminative and prognostic potential of cerebrospinal fluid phosphoTau\/tau ratio and neurofilaments for frontotemporal dementia subtypes. Alzheimer\u2019s Dement Diagnosis, Assess Dis Monit. 2015;1:505\u201312. \n                    https:\/\/doi.org\/10.1016\/j.dadm.2015.11.001","journal-title":"Alzheimer\u2019s Dement Diagnosis, Assess Dis Monit."},{"key":"364_CR41","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.neurobiolaging.2014.10.019","volume":"36","author":"C Wilke","year":"2015","unstructured":"Wilke C, Deuschle C, Rattay TW, Maetzler W, Synofzik M. Total tau is increased, but phosphorylated tau not decreased, in cerebrospinal fluid in amyotrophic lateral sclerosis. Neurobiol Aging. 2015;36:1072\u20134. \n                    https:\/\/doi.org\/10.1016\/j.neurobiolaging.2014.10.019","journal-title":"Neurobiol Aging."},{"key":"364_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0075091","volume":"8","author":"J Gaiottino","year":"2013","unstructured":"Gaiottino J, Norgren N, Dobson R, Topping J, Nissim A, Malaspina A, et al. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS One. 2013;8:e75091. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0075091","journal-title":"PLoS One."},{"key":"364_CR43","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/ana.24052","volume":"75","author":"CS Scherling","year":"2014","unstructured":"Scherling CS, Hall T, Berisha F, Klepac K, Karydas A, Coppola G, et al. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann Neurol. 2014;75:116\u201326. \n                    https:\/\/doi.org\/10.1002\/ana.24052","journal-title":"Ann Neurol."},{"key":"364_CR44","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1159\/000099473","volume":"23","author":"YAL Pijnenburg","year":"2007","unstructured":"Pijnenburg YAL, Janssen JC, Schoonenboom NSM, Petzold A, Mulder C, Stigbrand T, et al. CSF neurofilaments in frontotemporal dementia compared with early onset Alzheimer\u2019s disease and controls. Dement Geriatr Cogn Disord. 2007;23:225\u201330. \n                    https:\/\/doi.org\/10.1159\/000099473","journal-title":"Dement Geriatr Cogn Disord."},{"key":"364_CR45","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/acn3.325","volume":"3","author":"LH Meeter","year":"2016","unstructured":"Meeter LH, Dopper EG, Jiskoot LC, Sanchez-Valle R, Graff C, Benussi L, et al. Neurofilament light chain: a biomarker for genetic frontotemporal dementia. Ann Clin Transl Neurol. 2016;3:623\u201336. \n                    https:\/\/doi.org\/10.1002\/acn3.325","journal-title":"Ann Clin Transl Neurol."},{"key":"364_CR46","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1159\/000091436","volume":"21","author":"J Brettschneider","year":"2006","unstructured":"Brettschneider J, Petzold A, Schottle D, Claus A, Riepe M, Tumani H. The neurofilament heavy chain (NfH) in the cerebrospinal fluid diagnosis of Alzheimer\u2019s disease. Dement Geriatr Cogn Disord. 2006;21:291\u20135. \n                    https:\/\/doi.org\/10.1159\/000091436","journal-title":"Dement Geriatr Cogn Disord."},{"key":"364_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fneur.2015.00138","volume":"6","author":"H Struyfs","year":"2015","unstructured":"Struyfs H, Niemantsverdriet E, Goossens J, Fransen E, Martin J-J, De Deyn PP, et al. Cerebrospinal fluid p-tau181P: biomarker for improved differential dementia diagnosis. Front Neurol. 2015;6:1\u20138. \n                    https:\/\/doi.org\/10.3389\/fneur.2015.00138","journal-title":"Front Neurol."},{"key":"364_CR48","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3233\/JAD-141725","volume":"44","author":"JL Seeburger","year":"2015","unstructured":"Seeburger JL, Holder DJ, Combrinck M, Joachim C, Laterza O, Tanen M, et al. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer\u2019s disease from other dementias and healthy controls in the OPTIMA cohort. J Alzheimers Dis. 2015;44:525\u201339. \n                    https:\/\/doi.org\/10.3233\/JAD-141725","journal-title":"J Alzheimers Dis."},{"key":"364_CR49","doi-asserted-by":"publisher","first-page":"781","DOI":"10.3233\/JAD-2011-111046","volume":"27","author":"M Carecchio","year":"2011","unstructured":"Carecchio M, Fenoglio C, Cortini F, Comi C, Benussi L, Ghidoni R, et al. Cerebrospinal fluid biomarkers in progranulin mutations carriers. J Alzheimers Dis. 2011;27:781\u201390. \n                    https:\/\/doi.org\/10.3233\/JAD-2011-111046","journal-title":"J Alzheimers Dis."},{"key":"364_CR50","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1097\/nen.0b013e31803020cf","volume":"66","author":"KA Josephs","year":"2007","unstructured":"Josephs KA, Ahmed Z, Katsuse O, Parisi JF, Boeve BF, Knopman DS, et al. Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions with progranulin gene (PGRN) mutations. J Neuropathol Exp Neurol. 2007;66:142\u201351. \n                    https:\/\/doi.org\/10.1097\/nen.0b013e31803020cf","journal-title":"J Neuropathol Exp Neurol."},{"key":"364_CR51","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1001\/jamaneurol.2014.1316","volume":"71","author":"P Caroppo","year":"2014","unstructured":"Caroppo P, Le Ber I, Camuzat A, Clot F, Naccache L, Lamari F, et al. Extensive white matter involvement in patients with frontotemporal lobar degeneration. JAMA Neurol. 2014;71:1562. \n                    https:\/\/doi.org\/10.1001\/jamaneurol.2014.1316","journal-title":"JAMA Neurol."},{"key":"364_CR52","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/ene.12675","volume":"22","author":"JL Whitwell","year":"2015","unstructured":"Whitwell JL, Boeve BF, Weigand SD, Senjem ML, Gunter JL, Baker MC, et al. Brain atrophy over time in genetic and sporadic frontotemporal dementia: a study of 198 serial magnetic resonance images. Eur J Neurol. 2015;22:745\u201352. \n                    https:\/\/doi.org\/10.1111\/ene.12675","journal-title":"Eur J Neurol."},{"key":"364_CR53","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1093\/brain\/awv358","volume":"139","author":"S Van Mossevelde","year":"2016","unstructured":"Van Mossevelde S, van der Zee J, Gijselinck I, Engelborghs S, Sieben A, Van Langenhove T, et al. Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort. Brain. 2016;139:452\u201367. \n                    https:\/\/doi.org\/10.1093\/brain\/awv358","journal-title":"Brain."}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-018-0364-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13195-018-0364-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-018-0364-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T20:19:40Z","timestamp":1553026780000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-018-0364-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,20]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["364"],"URL":"https:\/\/doi.org\/10.1186\/s13195-018-0364-0","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,20]]},"assertion":[{"value":"15 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the ethics committee of the University of Antwerp, Antwerp, Belgium (B300201420405). Informed consent was obtained from all subjects.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"31"}}